1
|
Yan G, Rose J, Ellison C, Mudd AM, Zhang X, Wu S. Refine and Strengthen SAR-Based Read-Across by Considering Bioactivation and Modes of Action. Chem Res Toxicol 2023; 36:1532-1548. [PMID: 37594911 PMCID: PMC10523590 DOI: 10.1021/acs.chemrestox.3c00156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2023] [Indexed: 08/20/2023]
Abstract
Structure-activity relationship (SAR)-based read-across is an important and effective method to establish the safety of a data-poor target chemical (structure of interest (SOI)) using hazard data from structurally similar source chemicals (analogues). Many methods use quantitative similarity scores to evaluate the structural similarity for searching and selecting analogues as well as for evaluating analogue suitability. However, studies suggest that read-across based purely on structural similarity cannot accurately predict the toxicity of an SOI. As mechanistic data become available, we gain a greater understanding of the mode of action (MOA), the relationship between structures and metabolism/bioactivation pathways, and the existence of "activity cliffs" in chemical chain length, which can improve the analogue rating process. For this purpose, the current work identifies a series of classes of chemicals where a small change at a key position can result in a significant change in metabolism and bioactivation pathways and may eventually result in significant changes in chemical toxicity that have a big impact on the suitability of analogues for read-across. Additionally, a series of SAR-based read-across case studies are presented, which cover a variety of chemical classes that commonly link to different toxic endpoints. The case study results indicate that SAR-based read-across can be refined and strengthened by considering MOAs or proposed reactive metabolite formation pathways, which can improve the overall accuracy, consistency, transparency, and confidence in evaluating analogue suitability.
Collapse
Affiliation(s)
- Gang Yan
- Global Product
Stewardship, The Procter & Gamble Company, 8700 Mason Montgomery Rd., Mason, Ohio 45040, United States
| | - Jane Rose
- Global Product
Stewardship, The Procter & Gamble Company, 8700 Mason Montgomery Rd., Mason, Ohio 45040, United States
| | - Corie Ellison
- Global Product
Stewardship, The Procter & Gamble Company, 8700 Mason Montgomery Rd., Mason, Ohio 45040, United States
| | - Ashley M. Mudd
- Global Product
Stewardship, The Procter & Gamble Company, 8700 Mason Montgomery Rd., Mason, Ohio 45040, United States
| | - Xiaoling Zhang
- Global Product
Stewardship, The Procter & Gamble Company, 8700 Mason Montgomery Rd., Mason, Ohio 45040, United States
| | - Shengde Wu
- Global Product
Stewardship, The Procter & Gamble Company, 8700 Mason Montgomery Rd., Mason, Ohio 45040, United States
| |
Collapse
|
2
|
Sernoskie SC, Jee A, Uetrecht JP. The Emerging Role of the Innate Immune Response in Idiosyncratic Drug Reactions. Pharmacol Rev 2021; 73:861-896. [PMID: 34016669 DOI: 10.1124/pharmrev.120.000090] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Idiosyncratic drug reactions (IDRs) range from relatively common, mild reactions to rarer, potentially life-threatening adverse effects that pose significant risks to both human health and successful drug discovery. Most frequently, IDRs target the liver, skin, and blood or bone marrow. Clinical data indicate that most IDRs are mediated by an adaptive immune response against drug-modified proteins, formed when chemically reactive species of a drug bind to self-proteins, making them appear foreign to the immune system. Although much emphasis has been placed on characterizing the clinical presentation of IDRs and noting implicated drugs, limited research has focused on the mechanisms preceding the manifestations of these severe responses. Therefore, we propose that to address the knowledge gap between drug administration and onset of a severe IDR, more research is required to understand IDR-initiating mechanisms; namely, the role of the innate immune response. In this review, we outline the immune processes involved from neoantigen formation to the result of the formation of the immunologic synapse and suggest that this framework be applied to IDR research. Using four drugs associated with severe IDRs as examples (amoxicillin, amodiaquine, clozapine, and nevirapine), we also summarize clinical and animal model data that are supportive of an early innate immune response. Finally, we discuss how understanding the early steps in innate immune activation in the development of an adaptive IDR will be fundamental in risk assessment during drug development. SIGNIFICANCE STATEMENT: Although there is some understanding that certain adaptive immune mechanisms are involved in the development of idiosyncratic drug reactions, the early phase of these immune responses remains largely uncharacterized. The presented framework refocuses the investigation of IDR pathogenesis from severe clinical manifestations to the initiating innate immune mechanisms that, in contrast, may be quite mild or clinically silent. A comprehensive understanding of these early influences on IDR onset is crucial for accurate risk prediction, IDR prevention, and therapeutic intervention.
Collapse
Affiliation(s)
- Samantha Christine Sernoskie
- Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy (S.C.S., J.P.U.), and Department of Pharmacology and Toxicology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada (A.J., J.P.U.)
| | - Alison Jee
- Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy (S.C.S., J.P.U.), and Department of Pharmacology and Toxicology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada (A.J., J.P.U.)
| | - Jack Paul Uetrecht
- Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy (S.C.S., J.P.U.), and Department of Pharmacology and Toxicology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada (A.J., J.P.U.)
| |
Collapse
|
3
|
Hammond S, Thomson P, Meng X, Naisbitt D. In-Vitro Approaches to Predict and Study T-Cell Mediated Hypersensitivity to Drugs. Front Immunol 2021; 12:630530. [PMID: 33927714 PMCID: PMC8076677 DOI: 10.3389/fimmu.2021.630530] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2020] [Accepted: 03/17/2021] [Indexed: 01/11/2023] Open
Abstract
Mitigating the risk of drug hypersensitivity reactions is an important facet of a given pharmaceutical, with poor performance in this area of safety often leading to warnings, restrictions and withdrawals. In the last 50 years, efforts to diagnose, manage, and circumvent these obscure, iatrogenic diseases have resulted in the development of assays at all stages of a drugs lifespan. Indeed, this begins with intelligent lead compound selection/design to minimize the existence of deleterious chemical reactivity through exclusion of ominous structural moieties. Preclinical studies then investigate how compounds interact with biological systems, with emphasis placed on modeling immunological/toxicological liabilities. During clinical use, competent and accurate diagnoses are sought to effectively manage patients with such ailments, and pharmacovigilance datasets can be used for stratification of patient populations in order to optimise safety profiles. Herein, an overview of some of the in-vitro approaches to predict intrinsic immunogenicity of drugs and diagnose culprit drugs in allergic patients after exposure is detailed, with current perspectives and opportunities provided.
Collapse
Affiliation(s)
- Sean Hammond
- MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
- ApconiX, Alderley Park, Alderley Edge, United Kingdom
| | - Paul Thomson
- MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
| | - Xiaoli Meng
- MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
| | - Dean Naisbitt
- MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
| |
Collapse
|
4
|
Abstract
Cumulative research over several decades has implicated the involvement of reactive metabolites in many idiosyncratic adverse drug reactions (IADRs). Consequently, "avoidance" strategies have been inserted into drug discovery paradigms, which include the exclusion of structural alerts and possible termination of reactive metabolite-positive compounds. Several noteworthy examples where reactive metabolite-related liabilities have been resolved through structure-metabolism studies are presented herein. Considerable progress has also been made in addressing the limitations of the avoidance strategy and further refining the process of managing reactive metabolite issues in drug development. These efforts primarily stemmed from the observation that numerous drugs, which contain structural alerts and/or form reactive metabolites, are devoid of ADRs. The Perspective also dwells into an analysis of the structural alert/reactive metabolite concept with a discussion of risk mitigation tactics to support the progression of reactive metabolite-positive drug candidates.
Collapse
Affiliation(s)
- Amit S Kalgutkar
- Medicine Design, Pfizer Worldwide Research, Development and Medical, 1 Portland Street, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
5
|
Bolaji OO, Adehin A, Adeagbo BA. Pharmacogenomics in the Nigerian population: the past, the present and the future. Pharmacogenomics 2019; 20:915-926. [DOI: 10.2217/pgs-2019-0046] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
The Nigerian population exhibits huge ethnic and genetic diversity, typical of African populations, which can be harnessed for improved drug-response and disease management. Existing data on genes relevant to drug response, so far generated for the population, indeed confirm the prevalence of some clinically significant pharmacogenes. These reports detail prevailing genetic alleles and metabolic phenotypes of vital drug metabolizing monooxygenases, transferases and drug transporters. While the utilization of existing pharmacogenomic data for healthcare delivery remains unpopular, several past and on-going studies suggest that a future shift toward genotype-stratified dosing of drugs and disease management in the population is imminent. This review discusses the present state of pharmacogenomics in Nigeria and the potential benefits of sustained research in this field for the population.
Collapse
Affiliation(s)
- Oluseye O Bolaji
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria
| | - Ayorinde Adehin
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria
- Institute of Biomedical & Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, PR China
| | - Babatunde A Adeagbo
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria
| |
Collapse
|
6
|
The antimalarial drug amodiaquine stabilizes p53 through ribosome biogenesis stress, independently of its autophagy-inhibitory activity. Cell Death Differ 2019; 27:773-789. [PMID: 31285544 PMCID: PMC7205879 DOI: 10.1038/s41418-019-0387-5] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2018] [Revised: 06/09/2019] [Accepted: 06/21/2019] [Indexed: 12/11/2022] Open
Abstract
Pharmacological inhibition of ribosome biogenesis is a promising avenue for cancer therapy. Herein, we report a novel activity of the FDA-approved antimalarial drug amodiaquine which inhibits rRNA transcription, a rate-limiting step for ribosome biogenesis, in a dose-dependent manner. Amodiaquine triggers degradation of the catalytic subunit of RNA polymerase I (Pol I), with ensuing RPL5/RPL11-dependent stabilization of p53. Pol I shutdown occurs in the absence of DNA damage and without the subsequent ATM-dependent inhibition of rRNA transcription. RNAseq analysis revealed mechanistic similarities of amodiaquine with BMH-21, the first-in-class Pol I inhibitor, and with chloroquine, the antimalarial analog of amodiaquine, with well-established autophagy-inhibitory activity. Interestingly, autophagy inhibition caused by amodiaquine is not involved in the inhibition of rRNA transcription, suggesting two independent anticancer mechanisms. In vitro, amodiaquine is more efficient than chloroquine in restraining the proliferation of human cell lines derived from colorectal carcinomas, a cancer type with predicted susceptibility to ribosome biogenesis stress. Taken together, our data reveal an unsuspected activity of a drug approved and used in the clinics for over 30 years, and provide rationale for repurposing amodiaquine in cancer therapy.
Collapse
|
7
|
Klopčič I, Dolenc MS. Chemicals and Drugs Forming Reactive Quinone and Quinone Imine Metabolites. Chem Res Toxicol 2018; 32:1-34. [DOI: 10.1021/acs.chemrestox.8b00213] [Citation(s) in RCA: 41] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Affiliation(s)
- Ivana Klopčič
- University of Ljubljana, Faculty of Pharmacy, Aškerčeva 7, 1000 Ljubljana, Slovenia
| | | |
Collapse
|
8
|
Edema O, Adeagbo BA, Adehin A, Olugbade TA. Bidirectional Pharmacokinetic Interaction Between Amodiaquine and Pioglitazone in Healthy Subjects. J Clin Pharmacol 2018; 58:1061-1066. [DOI: 10.1002/jcph.1108] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2017] [Accepted: 01/26/2018] [Indexed: 11/10/2022]
Affiliation(s)
- Opeyemi Edema
- Department of Pharmaceutical Chemistry; Faculty of Pharmacy; Obafemi Awolowo University; Ile-Ife Nigeria
| | - Babatunde A. Adeagbo
- Department of Pharmaceutical Chemistry; Faculty of Pharmacy; Obafemi Awolowo University; Ile-Ife Nigeria
| | - Ayorinde Adehin
- Department of Pharmaceutical Chemistry; Faculty of Pharmacy; Obafemi Awolowo University; Ile-Ife Nigeria
| | - Tiwalade A. Olugbade
- Department of Pharmaceutical Chemistry; Faculty of Pharmacy; Obafemi Awolowo University; Ile-Ife Nigeria
| |
Collapse
|
9
|
Valverde EA, Romero AH, Acosta ME, Gamboa N, Henriques G, Rodrigues JR, Ciangherotti C, López SE. Synthesis, β-hematin inhibition studies and antimalarial evaluation of new dehydroxy isoquine derivatives against Plasmodium berghei: A promising antimalarial agent. Eur J Med Chem 2018; 148:498-506. [DOI: 10.1016/j.ejmech.2017.10.051] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2017] [Revised: 10/14/2017] [Accepted: 10/16/2017] [Indexed: 10/18/2022]
|
10
|
Dang NL, Hughes TB, Miller GP, Swamidass SJ. Computational Approach to Structural Alerts: Furans, Phenols, Nitroaromatics, and Thiophenes. Chem Res Toxicol 2017; 30:1046-1059. [PMID: 28256829 DOI: 10.1021/acs.chemrestox.6b00336] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Structural alerts are commonly used in drug discovery to identify molecules likely to form reactive metabolites and thereby become toxic. Unfortunately, as useful as structural alerts are, they do not effectively model if, when, and why metabolism renders safe molecules toxic. Toxicity due to a specific structural alert is highly conditional, depending on the metabolism of the alert, the reactivity of its metabolites, dosage, and competing detoxification pathways. A systems approach, which explicitly models these pathways, could more effectively assess the toxicity risk of drug candidates. In this study, we demonstrated that mathematical models of P450 metabolism can predict the context-specific probability that a structural alert will be bioactivated in a given molecule. This study focuses on the furan, phenol, nitroaromatic, and thiophene alerts. Each of these structural alerts can produce reactive metabolites through certain metabolic pathways but not always. We tested whether our metabolism modeling approach, XenoSite, can predict when a given molecule's alerts will be bioactivated. Specifically, we used models of epoxidation, quinone formation, reduction, and sulfur-oxidation to predict the bioactivation of furan-, phenol-, nitroaromatic-, and thiophene-containing drugs. Our models separated bioactivated and not-bioactivated furan-, phenol-, nitroaromatic-, and thiophene-containing drugs with AUC performances of 100%, 73%, 93%, and 88%, respectively. Metabolism models accurately predict whether alerts are bioactivated and thus serve as a practical approach to improve the interpretability and usefulness of structural alerts. We expect that this same computational approach can be extended to most other structural alerts and later integrated into toxicity risk models. This advance is one necessary step toward our long-term goal of building comprehensive metabolic models of bioactivation and detoxification to guide assessment and design of new therapeutic molecules.
Collapse
Affiliation(s)
- Na Le Dang
- Department of Pathology and Immunology, Washington University School of Medicine , Campus Box 8118, 660 S. Euclid Avenue, St. Louis, Missouri 63110, United States
| | - Tyler B Hughes
- Department of Pathology and Immunology, Washington University School of Medicine , Campus Box 8118, 660 S. Euclid Avenue, St. Louis, Missouri 63110, United States
| | - Grover P Miller
- Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences , Little Rock, Arkansas 72205, United States
| | - S Joshua Swamidass
- Department of Pathology and Immunology, Washington University School of Medicine , Campus Box 8118, 660 S. Euclid Avenue, St. Louis, Missouri 63110, United States
| |
Collapse
|
11
|
Hughes TB, Swamidass SJ. Deep Learning to Predict the Formation of Quinone Species in Drug Metabolism. Chem Res Toxicol 2017; 30:642-656. [PMID: 28099803 DOI: 10.1021/acs.chemrestox.6b00385] [Citation(s) in RCA: 43] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
Many adverse drug reactions are thought to be caused by electrophilically reactive drug metabolites that conjugate to nucleophilic sites within DNA and proteins, causing cancer or toxic immune responses. Quinone species, including quinone-imines, quinone-methides, and imine-methides, are electrophilic Michael acceptors that are often highly reactive and comprise over 40% of all known reactive metabolites. Quinone metabolites are created by cytochromes P450 and peroxidases. For example, cytochromes P450 oxidize acetaminophen to N-acetyl-p-benzoquinone imine, which is electrophilically reactive and covalently binds to nucleophilic sites within proteins. This reactive quinone metabolite elicits a toxic immune response when acetaminophen exceeds a safe dose. Using a deep learning approach, this study reports the first published method for predicting quinone formation: the formation of a quinone species by metabolic oxidation. We model both one- and two-step quinone formation, enabling accurate quinone formation predictions in nonobvious cases. We predict atom pairs that form quinones with an AUC accuracy of 97.6%, and we identify molecules that form quinones with 88.2% AUC. By modeling the formation of quinones, one of the most common types of reactive metabolites, our method provides a rapid screening tool for a key drug toxicity risk. The XenoSite quinone formation model is available at http://swami.wustl.edu/xenosite/p/quinone .
Collapse
Affiliation(s)
- Tyler B Hughes
- Department of Pathology and Immunology, Washington University School of Medicine , Campus Box 8118, 660 S. Euclid Avenue, St. Louis, Missouri 63110, United States
| | - S Joshua Swamidass
- Department of Pathology and Immunology, Washington University School of Medicine , Campus Box 8118, 660 S. Euclid Avenue, St. Louis, Missouri 63110, United States
| |
Collapse
|
12
|
Mishra M, Mishra VK, Kashaw V, Iyer AK, Kashaw SK. Comprehensive review on various strategies for antimalarial drug discovery. Eur J Med Chem 2016; 125:1300-1320. [PMID: 27886547 DOI: 10.1016/j.ejmech.2016.11.025] [Citation(s) in RCA: 65] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2016] [Revised: 11/07/2016] [Accepted: 11/11/2016] [Indexed: 01/14/2023]
Abstract
The resistance of malaria parasites to existing drugs carries on growing and progressively limiting our ability to manage this severe disease and finally lead to a massive global health burden. Till now, malaria control has relied upon the traditional quinoline, antifolate and artemisinin compounds. Very few new antimalarials were developed in the past 50 years. Among recent approaches, identification of novel chemotherapeutic targets, exploration of natural products with medicinal significance, covalent bitherapy having a dual mode of action into a single hybrid molecule and malaria vaccine development are explored heavily. The proper execution of these approaches and proper investment from international agencies will accelerate the discovery of drugs that provide new hope for the control or eventual eradication of this global infectious disease. This review explores various strategies for assessment and development of new antimalarial drugs. Current status and scientific value of previous approaches are systematically reviewed and new approaches provide a pragmatic forecast for future developments are introduced as well.
Collapse
Affiliation(s)
- Mitali Mishra
- Department of Pharmaceutical Sciences, Dr. Harisingh Gour University (A Central University), Sagar, MP, India
| | - Vikash K Mishra
- Department of Pharmaceutical Sciences, Dr. Harisingh Gour University (A Central University), Sagar, MP, India
| | - Varsha Kashaw
- SVN Institute of Pharmaceutical Sciences, SVN University, Sagar, MP, India
| | - Arun K Iyer
- Use-inspired Biomaterials & Integrated Nano Delivery (U-BiND) Systems Laboratory, Department of Pharmaceutical Sciences, Wayne State University, Detroit, MI, USA
| | - Sushil Kumar Kashaw
- Department of Pharmaceutical Sciences, Dr. Harisingh Gour University (A Central University), Sagar, MP, India; Use-inspired Biomaterials & Integrated Nano Delivery (U-BiND) Systems Laboratory, Department of Pharmaceutical Sciences, Wayne State University, Detroit, MI, USA.
| |
Collapse
|
13
|
Ryan E, Morrow BJ, Hemley CF, Pinson JA, Charman SA, Chiu FCK, Foitzik RC. Evidence for the in Vitro Bioactivation of Aminopyrazole Derivatives: Trapping Reactive Aminopyrazole Intermediates Using Glutathione Ethyl Ester in Human Liver Microsomes. Chem Res Toxicol 2015; 28:1747-52. [DOI: 10.1021/acs.chemrestox.5b00202] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Affiliation(s)
| | - Benjamin J. Morrow
- Cancer Therapeutics CRC, 343
Royal Parade, Parkville, Victoria 3052 Australia
| | - Catherine F. Hemley
- Cancer Therapeutics CRC, 343
Royal Parade, Parkville, Victoria 3052 Australia
| | - Jo-Anne Pinson
- Cancer Therapeutics CRC, 343
Royal Parade, Parkville, Victoria 3052 Australia
| | | | | | - Richard C. Foitzik
- Cancer Therapeutics CRC, 343
Royal Parade, Parkville, Victoria 3052 Australia
| |
Collapse
|
14
|
Romero AH, Acosta ME, Gamboa N, Charris JE, Salazar J, López SE. Synthesis, β-hematin inhibition studies and antimalarial evaluation of dehydroxy isotebuquine derivatives against Plasmodium berghei. Bioorg Med Chem 2015; 23:4755-4762. [DOI: 10.1016/j.bmc.2015.05.040] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2015] [Revised: 05/15/2015] [Accepted: 05/24/2015] [Indexed: 11/29/2022]
|
15
|
Desai KR, Rajput DK, Patel PB, Highland HN. Ameliorative Effects of Curcumin on Artesunate-Induced Subchronic Toxicity in Testis of Swiss Albino Male Mice. Dose Response 2015; 13:1559325815592393. [PMID: 26673878 PMCID: PMC4674183 DOI: 10.1177/1559325815592393] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
India is one of the endemic areas where control of malaria has become a formidable task. Artesunate is the current antimalarial drug used to treat malaria, especially chloroquine resistant. The objective of the present study was to investigate the dose-dependent effect of oral administration of artesunate on the oxidative parameters in testes of adult male Swiss albino mice and ameliorative efficacy of curcumin, a widely used antioxidant. An oral dose of 150 mg/kg body weight (bwt; low dose) and 300 mg/kg bwt (high dose) of artesunate was administered for a period of 45 days to male mice, and ameliorative efficacy of curcumin was also assessed. The results revealed that artesunate caused significant alteration in oxidative parameters in dose-dependent manner. Administration of artesunate brought about significant decrease in activities of superoxide dismutase, glutathione, glutathione peroxidase, and glutathione reductase, whereas lipid peroxidation and glutathione-S-transferase activity were found to be significantly increased. The results obtained show that oxidative insult is incurred upon the intracellular antioxidant system of testis tissue by artesunate treatment. Further, administration of curcumin at the dose level of 80 mg/kg bwt along with both doses of artesunate attenuated adverse effects in male mice.
Collapse
Affiliation(s)
- Ketaki R Desai
- Department of Zoology and BMT, Gujarat University, Ahmedabad, Gujarat, India
| | | | - Pragnesh B Patel
- Department of Zoology and BMT, Gujarat University, Ahmedabad, Gujarat, India
| | - Hyacinth N Highland
- Department of Zoology and BMT, Gujarat University, Ahmedabad, Gujarat, India
| |
Collapse
|
16
|
Korotchenko V, Sathunuru R, Gerena L, Caridha D, Li Q, Kreishman-Deitrick M, Smith PL, Lin AJ. Antimalarial activity of 4-amidinoquinoline and 10-amidinobenzonaphthyridine derivatives. J Med Chem 2015; 58:3411-31. [PMID: 25654185 DOI: 10.1021/jm501809x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Chloroquine (CQ) has been used as first line malaria therapeutic drug for decades. Emergence of CQ drug-resistant Plasmodium falciparum malaria throughout endemic areas of the world has limited its clinical value. Mefloquine (MQ) has been used as an effective malaria prophylactic drug due to its being long-acting and having a high potency against blood stage P. falciparum (Pf). However, serious CNS toxicity of MQ has compromised its clinical value as a prophylaxis drug. Therefore, new and inexpensive antimalarial drugs with no cross-resistance to CQ or CNS toxicity are urgently needed to combat this deadly human disease. In this study, a series of new 4-amidinoquinoline (4-AMQ) and 10-amidinobenzonaphthyridine (10-AMB) derivatives were designed, prepared, and assessed to search for new therapeutic agents to replace CQ and MQ. The new derivatives displayed high activity in vitro and in vivo, with no cross-resistance to CQ, and none were toxic in mice up to 160 mpk × 3. The best compound shows IC50 < 1 ng/mL against D6, W2 and C235 Pf clones, low inhibitory activity in hERG K(+) channel blockage testing, negativity in the Ames test, and 5/5 cure @ <15 mpk × 3 in mice infected with Plasmodium berghei. In addition to these desirable pharmacological profiles, compound 13b, one of the most active compounds, is metabolically stable in both human and mouse liver microsomal preparations and has a plasma t(1/2) of 50 h in mice, which made it a good MQ replacement candidate.
Collapse
Affiliation(s)
- Vasiliy Korotchenko
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, Maryland 20910, United States
| | - Ramadas Sathunuru
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, Maryland 20910, United States
| | - Lucia Gerena
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, Maryland 20910, United States
| | - Diana Caridha
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, Maryland 20910, United States
| | - Qigui Li
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, Maryland 20910, United States
| | - Mara Kreishman-Deitrick
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, Maryland 20910, United States
| | - Philip L Smith
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, Maryland 20910, United States
| | - Ai J Lin
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, Maryland 20910, United States
| |
Collapse
|
17
|
Stamper BD. Transcriptional profiling of reactive metabolites for elucidating toxicological mechanisms: a case study of quinoneimine-forming agents. Drug Metab Rev 2014; 47:45-55. [DOI: 10.3109/03602532.2014.978081] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|
18
|
Affiliation(s)
- David S Barnett
- Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital , Memphis, Tennessee 38105, United States
| | - R Kiplin Guy
- Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital , Memphis, Tennessee 38105, United States
| |
Collapse
|
19
|
Metushi IG, Cai P, Dervovic D, Liu F, Lobach A, Nakagawa T, Uetrecht J. Development of a novel mouse model of amodiaquine-induced liver injury with a delayed onset. J Immunotoxicol 2014; 12:247-60. [PMID: 25046026 DOI: 10.3109/1547691x.2014.934977] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Amodiaquine (AQ) treatment is associated with a high incidence of idiosyncratic drug-induced liver injury (IDILI) and agranulocytosis. Evidence suggests that AQ-induced IDILI is immune mediated. A significant impediment to mechanistic studies of IDILI is the lack of valid animal models. This study reports the first animal model of IDILI with characteristics similar to mild IDILI in humans. Treatment of female C57BL/6 mice with AQ led to liver injury with delayed onset, which resolved despite continued treatment. Covalent binding of AQ was detected in the liver, which was greater in female than in male mice, and higher in the liver than in other organs. Covalent binding in the liver was maximal by Day 3, which did not explain the delayed onset of alanine aminotransferase (ALT) elevation. However, coincident with the elevated serum ALT, infiltration of liver and splenic mononuclear cells and activation of CD8 T-cells within the liver were identified. By Week 7, when ALT levels had returned close to normal, down-regulation of several inflammatory cytokines and up-regulation of PD-1 on T-cells suggested induction of immune tolerance. Treatment of Rag1(-/-) mice with AQ resulted in higher ALT activities than C57BL/6 mice, which suggested that the adaptive immune response was responsible for immune tolerance. In contrast, depletion of NK cells significantly attenuated the increase in ALT, which implied a role for NK cells in mild AQ-induced IDILI. This is the first example of a delayed-onset animal model of IDILI that appears to be immune-mediated.
Collapse
Affiliation(s)
- Imir G Metushi
- Department of Pharmacology and Toxicology, Faculty of Medicine and
| | | | | | | | | | | | | |
Collapse
|
20
|
Lobach AR, Uetrecht J. Involvement of myeloperoxidase and NADPH oxidase in the covalent binding of amodiaquine and clozapine to neutrophils: implications for drug-induced agranulocytosis. Chem Res Toxicol 2014; 27:699-709. [PMID: 24588327 DOI: 10.1021/tx500019u] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Amodiaquine (AQ) and clozapine (CLZ) are associated with a relatively high incidence of idiosyncratic agranulocytosis, a reaction that is suspected to involve covalent binding of reactive metabolites to neutrophils. Previous studies have shown that both AQ and CLZ are oxidized to reactive intermediates in vitro by activated neutrophils or by the combination of hydrogen peroxide and myeloperoxidase (MPO). Neutrophil activation leads to an oxidative burst with activation of NADPH oxidase and the production of hydrogen peroxide. However, the importance of this pathway in covalent binding in vivo has not been examined. In this study, we found that the binding of both AQ and CLZ to neutrophils from MPO knockout mice ex vivo decreased approximately 2-fold compared to neutrophils from wild-type mice, whereas binding to activated neutrophils from gp91 knockout (NADPH oxidase null) mice decreased 6-7-fold. When the AQ studies were performed in vivo, again the binding was decreased in MPO knockout mice to about 50% of the binding in wild-type mice; however, covalent binding was significant in the absence of MPO. Surprisingly, there was no significant decrease in covalent binding of AQ to neutrophils in vivo in gp91 knockout mice. In addition, there was extensive binding of AQ to many types of bone marrow cells and to peripheral lymphocytes. These results indicate that MPO is not the only neutrophil enzyme involved in the oxidation of AQ and that NADPH oxidase is not the major source of peroxide. There was also no decrease in AQ binding to neutrophils in COX-1 or COX-2 knockout mice. We were not able to readily reproduce the AQ in vivo studies with CLZ because of its acute toxicity in mice. These are the first studies to examine the enzymes involved in the bioactivation of AQ by neutrophils in vivo.
Collapse
Affiliation(s)
- Alexandra R Lobach
- Department of Pharmaceutical Sciences, Faculty of Pharmacy, University of Toronto , Toronto, Ontario M5S 3M2, Canada
| | | |
Collapse
|
21
|
Qiao S, Tao S, Rojo de la Vega M, Park SL, Vonderfecht AA, Jacobs SL, Zhang DD, Wondrak GT. The antimalarial amodiaquine causes autophagic-lysosomal and proliferative blockade sensitizing human melanoma cells to starvation- and chemotherapy-induced cell death. Autophagy 2013; 9:2087-102. [PMID: 24113242 DOI: 10.4161/auto.26506] [Citation(s) in RCA: 59] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
Pharmacological inhibition of autophagic-lysosomal function has recently emerged as a promising strategy for chemotherapeutic intervention targeting cancer cells. Repurposing approved and abandoned non-oncological drugs is an alternative approach to the identification and development of anticancer therapeutics, and antimalarials that target autophagic-lysosomal functions have recently attracted considerable attention as candidates for oncological repurposing. Since cumulative research suggests that dependence on autophagy represents a specific vulnerability of malignant melanoma cells, we screened a focused compound library of antimalarials for antimelanoma activity. Here we report for the first time that amodiaquine (AQ), a clinical 4-aminoquinoline antimalarial with unexplored cancer-directed chemotherapeutic potential, causes autophagic-lysosomal and proliferative blockade in melanoma cells that surpasses that of its parent compound chloroquine. Monitoring an established set of protein markers (LAMP1, LC3-II, SQSTM1) and cell ultrastructural changes detected by electron microscopy, we observed that AQ treatment caused autophagic-lysosomal blockade in malignant A375 melanoma cells, a finding substantiated by detection of rapid inactivation of lysosomal cathepsins (CTSB, CTSL, CTSD). AQ-treatment was associated with early induction of energy crisis (ATP depletion) and sensitized melanoma cells to either starvation- or chemotherapeutic agent-induced cell death. AQ displayed potent antiproliferative effects, and gene expression array analysis revealed changes at the mRNA (CDKN1A, E2F1) and protein level (TP53, CDKN1A, CCND1, phospho-RB1 [Ser 780]/[Ser 807/811], E2F1) consistent with the observed proliferative blockade in S-phase. Taken together, our data suggest that the clinical antimalarial AQ is a promising candidate for repurposing efforts that aim at targeting autophagic-lysosomal function and proliferative control in malignant melanoma cells.
Collapse
Affiliation(s)
- Shuxi Qiao
- Department of Pharmacology and Toxicology; College of Pharmacy and Arizona Cancer Center; University of Arizona; Tucson, AZ USA
| | | | | | | | | | | | | | | |
Collapse
|
22
|
Rebecca C Elton Michael J Garle Jeffrey R Fry. Glutathione depletion in a liver microsomal assay as an in vitro biomarker for reactive metabolite formation. Biomarkers 2013; 5:285-94. [PMID: 23885981 DOI: 10.1080/135475000413836] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Glutathione (GSH) plays a major role in cytoprotection, acting as a nucleophile trap for reactive species derived from xenobiotics. This has led to the development of an assay for the detection of reactive species generated by liver microsomal metabolism of xenobiotics. This assay has been used extensively to study reactive metabolites which initiate toxicity through a direct (non-immunological) mechanism, but there are few data on its ability to detect reactive metabolites that initiate toxicity through neo-antigen formation, or to detect xenobiotics that cause GSH loss by oxidation mediated by a redox cycling process. Accordingly, the ability of rat and human liver microsomes to metabolize xenobiotics to GSH-depleting metabolites has been investigated further. Of the five neo-antigen-forming xenobiotics tested, four (amodiaquine, phenobarbitone, procainamide, and sulphanilamide) displayed GSH reactivity that was either dependent or independent (amodiaquine) on metabolism. The other neo-antigen-forming xenobiotic (carbamazepine) was inactive in all microsomal samples tested. Four quinones believed to exert toxcity through arylation (1,4-benzoquinone) and/or redox cycling (duroquinone, menadione, mitomycin c) displayed GSH reactivity, as did nitrofurantoin and diquat, two other redox cycling xenobiotics. Induction of the mixed function oxidase system with Aroclor afforded little advantage when using rat liver microsomes, whilst there was considerable inter-individual variation in the ability of human liver microsomes to mediate metabolism-dependent GSH depletion. It is concluded that the liver microsome GSH depletion assay may be of general utility as a screen for a number of xenobiotic-derived reactive species.
Collapse
|
23
|
Topological Features in Profiling the Antimalarial Activity Landscape of Anilinoquinolines: A Multipronged QSAR Study. J CHEM-NY 2013. [DOI: 10.1155/2013/154629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
24
|
Novel in vivo active anti-malarials based on a hydroxy-ethyl-amine scaffold. Bioorg Med Chem Lett 2012; 23:658-62. [PMID: 23260352 DOI: 10.1016/j.bmcl.2012.11.118] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2012] [Revised: 11/28/2012] [Accepted: 11/29/2012] [Indexed: 11/20/2022]
Abstract
A novel series of anti-malarials, based on a hydroxy-ethyl-amine scaffold, initially identified as peptidomimetic protease inhibitors is described. Combination of the hydroxy-ethyl-amine anti-malarial phramacophore with the known Mannich base pharmacophore of amodiaquine (57) resulted in promising in vivo active novel derivatives.
Collapse
|
25
|
Gemma S, Camodeca C, Brindisi M, Brogi S, Kukreja G, Kunjir S, Gabellieri E, Lucantoni L, Habluetzel A, Taramelli D, Basilico N, Gualdani R, Tadini-Buoninsegni F, Bartolommei G, Moncelli MR, Martin RE, Summers RL, Lamponi S, Savini L, Fiorini I, Valoti M, Novellino E, Campiani G, Butini S. Mimicking the Intramolecular Hydrogen Bond: Synthesis, Biological Evaluation, and Molecular Modeling of Benzoxazines and Quinazolines as Potential Antimalarial Agents. J Med Chem 2012; 55:10387-404. [DOI: 10.1021/jm300831b] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Sandra Gemma
- European Research Centre for
Drug Discovery and Development (NatSynDrugs), University of Siena,
Via Aldo Moro, 53100 Siena, Italy
- CIRM Centro Interuniversitario
di Ricerche sulla Malaria, Università di Torino, Torino, Italy
| | - Caterina Camodeca
- European Research Centre for
Drug Discovery and Development (NatSynDrugs), University of Siena,
Via Aldo Moro, 53100 Siena, Italy
- CIRM Centro Interuniversitario
di Ricerche sulla Malaria, Università di Torino, Torino, Italy
| | - Margherita Brindisi
- European Research Centre for
Drug Discovery and Development (NatSynDrugs), University of Siena,
Via Aldo Moro, 53100 Siena, Italy
- CIRM Centro Interuniversitario
di Ricerche sulla Malaria, Università di Torino, Torino, Italy
| | - Simone Brogi
- European Research Centre for
Drug Discovery and Development (NatSynDrugs), University of Siena,
Via Aldo Moro, 53100 Siena, Italy
- CIRM Centro Interuniversitario
di Ricerche sulla Malaria, Università di Torino, Torino, Italy
| | - Gagan Kukreja
- European Research Centre for
Drug Discovery and Development (NatSynDrugs), University of Siena,
Via Aldo Moro, 53100 Siena, Italy
- CIRM Centro Interuniversitario
di Ricerche sulla Malaria, Università di Torino, Torino, Italy
| | - Sanil Kunjir
- European Research Centre for
Drug Discovery and Development (NatSynDrugs), University of Siena,
Via Aldo Moro, 53100 Siena, Italy
- CIRM Centro Interuniversitario
di Ricerche sulla Malaria, Università di Torino, Torino, Italy
| | - Emanuele Gabellieri
- European Research Centre for
Drug Discovery and Development (NatSynDrugs), University of Siena,
Via Aldo Moro, 53100 Siena, Italy
- CIRM Centro Interuniversitario
di Ricerche sulla Malaria, Università di Torino, Torino, Italy
| | - Leonardo Lucantoni
- CIRM Centro Interuniversitario
di Ricerche sulla Malaria, Università di Torino, Torino, Italy
- Scuola di Scienze del Farmaco
e dei Prodotti della Salute, Università di Camerino, 62032
Camerino (MC), Italy
| | - Annette Habluetzel
- CIRM Centro Interuniversitario
di Ricerche sulla Malaria, Università di Torino, Torino, Italy
- Scuola di Scienze del Farmaco
e dei Prodotti della Salute, Università di Camerino, 62032
Camerino (MC), Italy
| | - Donatella Taramelli
- European Research Centre for
Drug Discovery and Development (NatSynDrugs), University of Siena,
Via Aldo Moro, 53100 Siena, Italy
- CIRM Centro Interuniversitario
di Ricerche sulla Malaria, Università di Torino, Torino, Italy
| | - Nicoletta Basilico
- European Research Centre for
Drug Discovery and Development (NatSynDrugs), University of Siena,
Via Aldo Moro, 53100 Siena, Italy
- CIRM Centro Interuniversitario
di Ricerche sulla Malaria, Università di Torino, Torino, Italy
| | - Roberta Gualdani
- Department of Chemistry “Ugo
Schiff”, University of Florence, 50019 Sesto Fiorentino, Italy
| | | | - Gianluca Bartolommei
- Department of Chemistry “Ugo
Schiff”, University of Florence, 50019 Sesto Fiorentino, Italy
| | - Maria Rosa Moncelli
- Department of Chemistry “Ugo
Schiff”, University of Florence, 50019 Sesto Fiorentino, Italy
| | - Rowena E. Martin
- Research School of Biology,
The Australian National University, Canberra ACT 0200, Australia
| | - Robert L. Summers
- Research School of Biology,
The Australian National University, Canberra ACT 0200, Australia
| | - Stefania Lamponi
- European Research Centre for
Drug Discovery and Development (NatSynDrugs), University of Siena,
Via Aldo Moro, 53100 Siena, Italy
- CIRM Centro Interuniversitario
di Ricerche sulla Malaria, Università di Torino, Torino, Italy
| | - Luisa Savini
- European Research Centre for
Drug Discovery and Development (NatSynDrugs), University of Siena,
Via Aldo Moro, 53100 Siena, Italy
- CIRM Centro Interuniversitario
di Ricerche sulla Malaria, Università di Torino, Torino, Italy
| | - Isabella Fiorini
- European Research Centre for
Drug Discovery and Development (NatSynDrugs), University of Siena,
Via Aldo Moro, 53100 Siena, Italy
- CIRM Centro Interuniversitario
di Ricerche sulla Malaria, Università di Torino, Torino, Italy
| | - Massimo Valoti
- Dipartimento di Neuroscienze,
University of Siena, via A. Moro 2, Siena, Italy
| | - Ettore Novellino
- European Research Centre for
Drug Discovery and Development (NatSynDrugs), University of Siena,
Via Aldo Moro, 53100 Siena, Italy
- Dipartimento di Chimica Farmaceutica
e Tossicologica, University of Naples Federico II, Via D. Montesano
49, 80131 Naples, Italy
| | - Giuseppe Campiani
- European Research Centre for
Drug Discovery and Development (NatSynDrugs), University of Siena,
Via Aldo Moro, 53100 Siena, Italy
- CIRM Centro Interuniversitario
di Ricerche sulla Malaria, Università di Torino, Torino, Italy
| | - Stefania Butini
- European Research Centre for
Drug Discovery and Development (NatSynDrugs), University of Siena,
Via Aldo Moro, 53100 Siena, Italy
- CIRM Centro Interuniversitario
di Ricerche sulla Malaria, Università di Torino, Torino, Italy
| |
Collapse
|
26
|
|
27
|
Abstract
It is generally believed that metabolic bioactivation of drug molecules to form reactive metabolites, followed by their covalent binding to endogenous macromolecules, is one of the mechanisms that can lead to hepatotoxicity or idiosyncratic adverse drug reactions (IADRs). Although the role of bioactivation in drug-induced liver injury has been reasonably well established and accepted, and methodologies (e.g., structural alerts, reactive metabolite trapping, and covalent binding) continue to emerge in an attempt to detect the occurrence of bioactivation, the challenge remains to accurately predict the likelihood for idiosyncratic liver toxicity. Recent advances in risk-assessment methodologies, such as by the estimate of total body burden of covalent binding or by zone classification, taking the clinical dose into consideration, are positive steps toward improving risk assessment. The ability to better predict the potential of a drug candidate to cause IADRs will further be dependent upon a better understanding of the pathophysiological mechanisms of such reactions. Until a thorough understanding of the relationship between liver toxicity and the formation of reactive metabolites is achieved, it appears, at present, that the most practical strategy in drug discovery and development to reduce the likelihood of idiosyncratic liver toxicity via metabolic activation is to minimize or eliminate the occurrence of bioactivation and, at the same time, to maximize the pharmacological potency (to minimze the clinical dose) of the drug of interest.
Collapse
Affiliation(s)
- Louis Leung
- Pharmacokinetics, Dynamics, and Metabolism Department, Pfizer Global Research and Development, Groton, Connecticut 06340-5196, USA.
| | | | | |
Collapse
|
28
|
Stepan AF, Walker DP, Bauman J, Price DA, Baillie TA, Kalgutkar AS, Aleo MD. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chem Res Toxicol 2011; 24:1345-410. [PMID: 21702456 DOI: 10.1021/tx200168d] [Citation(s) in RCA: 486] [Impact Index Per Article: 37.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Because of a preconceived notion that eliminating reactive metabolite (RM) formation with new drug candidates could mitigate the risk of idiosyncratic drug toxicity, the potential for RM formation is routinely examined as part of lead optimization efforts in drug discovery. Likewise, avoidance of "structural alerts" is almost a norm in drug design. However, there is a growing concern that the perceived safety hazards associated with structural alerts and/or RM screening tools as standalone predictors of toxicity risks may be over exaggerated. In addition, the multifactorial nature of idiosyncratic toxicity is now well recognized based upon observations that mechanisms other than RM formation (e.g., mitochondrial toxicity and inhibition of bile salt export pump (BSEP)) also can account for certain target organ toxicities. Hence, fundamental questions arise such as: When is a molecule that contains a structural alert (RM positive or negative) a cause for concern? Could the molecule in its parent form exert toxicity? Can a low dose drug candidate truly mitigate metabolism-dependent and -independent idiosyncratic toxicity risks? In an effort to address these questions, we have retrospectively examined 68 drugs (recalled or associated with a black box warning due to idiosyncratic toxicity) and the top 200 drugs (prescription and sales) in the United States in 2009 for trends in physiochemical characteristics, daily doses, presence of structural alerts, evidence for RM formation as well as toxicity mechanism(s) potentially mediated by parent drugs. Collectively, our analysis revealed that a significant proportion (∼78-86%) of drugs associated with toxicity contained structural alerts and evidence indicating that RM formation as a causative factor for toxicity has been presented in 62-69% of these molecules. In several cases, mitochondrial toxicity and BSEP inhibition mediated by parent drugs were also noted as potential causative factors. Most drugs were administered at daily doses exceeding several hundred milligrams. There was no obvious link between idiosyncratic toxicity and physicochemical properties such as molecular weight, lipophilicity, etc. Approximately half of the top 200 drugs for 2009 (prescription and sales) also contained one or more alerts in their chemical architecture, and many were found to be RM-positive. Several instances of BSEP and mitochondrial liabilities were also noted with agents in the top 200 category. However, with relatively few exceptions, the vast majority of these drugs are rarely associated with idiosyncratic toxicity, despite years of patient use. The major differentiating factor appeared to be the daily dose; most of the drugs in the top 200 list are administered at low daily doses. In addition, competing detoxication pathways and/or alternate nonmetabolic clearance routes provided suitable justifications for the safety records of RM-positive drugs in the top 200 category. Thus, while RM elimination may be a useful and pragmatic starting point in mitigating idiosyncratic toxicity risks, our analysis suggests a need for a more integrated screening paradigm for chemical hazard identification in drug discovery. Thus, in addition to a detailed assessment of RM formation potential (in relationship to the overall elimination mechanisms of the compound(s)) for lead compounds, effects on cellular health (e.g., cytotoxicity assays), BSEP inhibition, and mitochondrial toxicity are the recommended suite of assays to characterize compound liabilities. However, the prospective use of such data in compound selection will require further validation of the cellular assays using marketed agents. Until we gain a better understanding of the pathophysiological mechanisms associated with idiosyncratic toxicities, improving pharmacokinetics and intrinsic potency as means of decreasing the dose size and the associated "body burden" of the parent drug and its metabolites will remain an overarching goal in drug discovery.
Collapse
Affiliation(s)
- Antonia F Stepan
- Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, USA
| | | | | | | | | | | | | |
Collapse
|
29
|
Le Fur N, Hochart G, Larchanché PE, Melnyk P. Buchwald reaction as the key step for the synthesis of metabolically more stable analogs of amodiaquine. Eur J Med Chem 2011; 46:3052-7. [DOI: 10.1016/j.ejmech.2011.04.047] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2011] [Revised: 04/14/2011] [Accepted: 04/15/2011] [Indexed: 11/30/2022]
|
30
|
Kalgutkar AS. Handling reactive metabolite positives in drug discovery: What has retrospective structure-toxicity analyses taught us? Chem Biol Interact 2010; 192:46-55. [PMID: 20833160 DOI: 10.1016/j.cbi.2010.09.003] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2010] [Revised: 08/30/2010] [Accepted: 09/02/2010] [Indexed: 11/26/2022]
Abstract
Because of the inability to predict and quantify the risk of idiosyncratic adverse drug reactions (IADRs) and because reactive metabolites (RMs) as opposed to the parent molecules from which they are derived are thought to be responsible for the pathogenesis of some IADRs, procedures (RM trapping/covalent binding) are being incorporated into the discovery screening funnel early-on to assess the risk of RM formation. Utility of the methodology in structure-toxicity relationships and scope in abrogating RM formation at the lead optimization stage are discussed in this article. Interpretation of the output from RM assessment assays, however, is confounded by the fact that many successfully marketed drugs are false positives. Therefore, caution must be exercised in deprioritizing a compound based on a positive result, so that the development of a useful and potentially profitable compound won't be unnecessarily halted. Risk mitigation strategies (e.g., competing detoxication pathways, low daily dose, etc.) when selecting RM positives for clinical development are also reviewed.
Collapse
Affiliation(s)
- Amit S Kalgutkar
- Pharmacokinetics, Dynamics and Metabolism Department, Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA.
| |
Collapse
|
31
|
Driscoll JP, Aliagas I, Harris JJ, Halladay JS, Khatib-Shahidi S, Deese A, Segraves N, Khojasteh-Bakht SC. Formation of a Quinoneimine Intermediate of 4-Fluoro-N-methylaniline by FMO1: Carbon Oxidation Plus Defluorination. Chem Res Toxicol 2010; 23:861-3. [DOI: 10.1021/tx1000688] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Affiliation(s)
- James P. Driscoll
- Departments of Drug Metabolism and Pharmacokinetics, Small Molecule Analytical Chemistry, and Computational Chemistry & Cheminformatics, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080
| | - Ignacio Aliagas
- Departments of Drug Metabolism and Pharmacokinetics, Small Molecule Analytical Chemistry, and Computational Chemistry & Cheminformatics, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080
| | - Jennifer J. Harris
- Departments of Drug Metabolism and Pharmacokinetics, Small Molecule Analytical Chemistry, and Computational Chemistry & Cheminformatics, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080
| | - Jason S. Halladay
- Departments of Drug Metabolism and Pharmacokinetics, Small Molecule Analytical Chemistry, and Computational Chemistry & Cheminformatics, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080
| | - Sheerin Khatib-Shahidi
- Departments of Drug Metabolism and Pharmacokinetics, Small Molecule Analytical Chemistry, and Computational Chemistry & Cheminformatics, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080
| | - Alan Deese
- Departments of Drug Metabolism and Pharmacokinetics, Small Molecule Analytical Chemistry, and Computational Chemistry & Cheminformatics, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080
| | - Nathaniel Segraves
- Departments of Drug Metabolism and Pharmacokinetics, Small Molecule Analytical Chemistry, and Computational Chemistry & Cheminformatics, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080
| | - S. Cyrus Khojasteh-Bakht
- Departments of Drug Metabolism and Pharmacokinetics, Small Molecule Analytical Chemistry, and Computational Chemistry & Cheminformatics, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080
| |
Collapse
|
32
|
Fur NL, Larchanché PE, Melnyk P. Optimized and convergent synthesis of potent anti-malarial aminoquinoline compounds: easy access to analogs. HETEROCYCL COMMUN 2010. [DOI: 10.1515/hc.2010.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
33
|
Abstract
Drugs are generally converted to biologically inactive forms and eliminated from the body, principally by hepatic metabolism. However, certain drugs undergo biotransformation to metabolites that can interfere with cellular functions through their intrinsic chemical reactivity towards glutathione, leading to thiol depletion, and functionally critical macromolecules, resulting in reversible modification, irreversible adduct formation, and irreversible loss of activity. There is now a great deal of evidence which shows that reactive metabolites are formed from drugs known to cause hepatotoxicity, such as acetaminophen, tamoxifen, isoniazid, and amodiaquine. The main theme of this article is to review the evidence for chemically reactive metabolites being initiating factors for the multiple downstream biological events culminating in toxicity. The major objectives are to understand those idiosyncratic hepatotoxicities thought to be caused by chemically reactive metabolites and to define the role of toxic metabolites.
Collapse
|
34
|
D'Alessandro U. Existing antimalarial agents and malaria-treatment strategies. Expert Opin Pharmacother 2009; 10:1291-306. [PMID: 19463069 DOI: 10.1517/14656560902942319] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
In the absence of prompt and efficacious treatment, malaria patients may progress within a few hours from having minor symptoms to severe disease and death. These last years have seen the development of several artemisinin-based combinations, new treatments for severe malaria patients, and new strategies such as intermittent preventive treatment or the home-based/near-home management of malaria. The health sector is now confronted with several treatment options and strategies, in contrast with the period when chloroquine monotherapy was the standard treatment. The major challenge remains the large-scale deployment, in the most efficient way, of the tools available today, including artemisinin-based combination treatments, within health systems that remain extremely weak in malaria endemic countries, particularly in sub-Saharan Africa. Health system research, exploring new potential approaches for the large-scale implementation of these interventions, should be promoted in parallel with that on new therapeutic agents to be used in the unlucky event of the emergence and spread of artemisinin resistance. The prospects of substantially decreasing the malaria burden are brighter today than 20 - 30 years ago, but the efforts and resources committed to this purpose should be maintained over a long period.
Collapse
Affiliation(s)
- Umberto D'Alessandro
- Department of Parasitology, Institute of Tropical Medicine, Nationalestraat 10, B-2000 Antwerp, Belgium.
| |
Collapse
|
35
|
Păunescu E, Susplugas S, Boll E, Varga R, Mouray E, Grosu I, Grellier P, Melnyk P. Replacement of the 4'-hydroxy group of amodiaquine and amopyroquine by aromatic and aliphatic substituents: synthesis and antimalarial activity. ChemMedChem 2009; 4:549-61. [PMID: 19212949 DOI: 10.1002/cmdc.200800318] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
The prophylactic administration of amodiaquine (AQ), a 4-aminoquinoline antimalarial drug, has been associated with side effects such as agranulocytosis and liver damage. The toxicity of this drug is mediated by amodiaquine quinone-imine, an electrophilic metabolite. Replacement of the 4'-hydroxy function of AQ with various alkyl, aryl, or heteroaryl substituents would provide analogues that avoid metabolism to potentially toxic derivatives. Following a multistep procedure, 33 compounds containing hydrophobic groups at the 4'-position were synthesized using Csp(2)-Csp(2) and Csp(2)-Csp(3) Suzuki-Miyaura cross-coupling reactions as the key step. The new derivatives were found to be active against both chloroquine (CQ)-sensitive and CQ-resistant strains of P. falciparum, with IC(50) values in the range of 7-200 nM. Alkyl analogues are more efficient than aryl or heteroaryl derivatives. All compounds were also assessed for their cytotoxicity and ability to inhibit beta-hematin formation in vitro. A detailed investigation of the structure-activity relationships for these new compounds was carried out; the 4'-methyl compound showed interesting in vivo antimalarial activity.
Collapse
|
36
|
Ismail FMD, Drew MGB, Navaratnam S, Bisby RH. A pulse radiolysis study of free radicals formed by one-electron oxidation of the antimalarial drug pyronaridine. RESEARCH ON CHEMICAL INTERMEDIATES 2009. [DOI: 10.1007/s11164-009-0051-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
37
|
Abstract
Central to most hypotheses of the mechanism of idiosyncratic drug-induced blood dyscrasias is the involvement of reactive metabolites. In view of the reactive nature of the majority of such metabolites, it is likely that they are formed by, or in close proximity to the blood cells affected. The major oxidative system of neutrophils generates hypochlorous acid. We have demonstrated that the drugs associated with the highest incidence of agranulocytosis are oxidized to reactive metabolites by hypochlorous acid and/or activated neutrophils. There are many mechanisms by which such reactive metabolites could induce agranulocytosis. In the case of aminopyrine-induced agranulocytosis, most cases appear to involve drug-dependent anti-neutrophil antibodies, and these are likely to be induced by cell membrane antigens modified by the reactive metabolite of aminopyrine. The target of agranulocytosis associated with many other drugs is usually neutrophil precursors and may involve cytotoxicity or a cell-mediated immune reaction induced by a reactive metabolite. In the case of aplastic anaemia, there is evidence in some cases for involvement of cytotoxic T cells, which could either be induced by metabolites generated by neutrophils, or more likely, by reactive metabolites generated by stem cells.
Collapse
Affiliation(s)
- J P Uetrecht
- Faculty of Pharmacy, University of Toronto, Canada
| |
Collapse
|
38
|
O’Neill PM, Shone AE, Stanford D, Nixon G, Asadollahy E, Park BK, Maggs JL, Roberts P, Stocks PA, Biagini G, Bray PG, Davies J, Berry N, Hall C, Rimmer K, Winstanley PA, Hindley S, Bambal RB, Davis CB, Bates M, Gresham SL, Brigandi RA, Gomez-de-las-Heras FM, Gargallo DV, Parapini S, Vivas L, Lander H, Taramelli D, Ward SA. Synthesis, Antimalarial Activity, and Preclinical Pharmacology of a Novel Series of 4′-Fluoro and 4′-Chloro Analogues of Amodiaquine. Identification of a Suitable “Back-Up” Compound for N-tert-Butyl Isoquine. J Med Chem 2009; 52:1828-44. [DOI: 10.1021/jm8012757] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Paul M. O’Neill
- Department of Chemistry, University of Liverpool, Liverpool L69 7ZD, U.K., MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, School of Biomedical Sciences, University of Liverpool, Liverpool L69 3GE, U.K., Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K., Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Drug Discovery, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, Medicines Research Centre, GlaxoSmithKline, Gunnels Wood
| | - Alison E. Shone
- Department of Chemistry, University of Liverpool, Liverpool L69 7ZD, U.K., MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, School of Biomedical Sciences, University of Liverpool, Liverpool L69 3GE, U.K., Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K., Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Drug Discovery, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, Medicines Research Centre, GlaxoSmithKline, Gunnels Wood
| | - Deborah Stanford
- Department of Chemistry, University of Liverpool, Liverpool L69 7ZD, U.K., MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, School of Biomedical Sciences, University of Liverpool, Liverpool L69 3GE, U.K., Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K., Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Drug Discovery, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, Medicines Research Centre, GlaxoSmithKline, Gunnels Wood
| | - Gemma Nixon
- Department of Chemistry, University of Liverpool, Liverpool L69 7ZD, U.K., MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, School of Biomedical Sciences, University of Liverpool, Liverpool L69 3GE, U.K., Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K., Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Drug Discovery, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, Medicines Research Centre, GlaxoSmithKline, Gunnels Wood
| | - Eghbaleh Asadollahy
- Department of Chemistry, University of Liverpool, Liverpool L69 7ZD, U.K., MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, School of Biomedical Sciences, University of Liverpool, Liverpool L69 3GE, U.K., Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K., Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Drug Discovery, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, Medicines Research Centre, GlaxoSmithKline, Gunnels Wood
| | - B. Kevin Park
- Department of Chemistry, University of Liverpool, Liverpool L69 7ZD, U.K., MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, School of Biomedical Sciences, University of Liverpool, Liverpool L69 3GE, U.K., Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K., Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Drug Discovery, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, Medicines Research Centre, GlaxoSmithKline, Gunnels Wood
| | - James L. Maggs
- Department of Chemistry, University of Liverpool, Liverpool L69 7ZD, U.K., MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, School of Biomedical Sciences, University of Liverpool, Liverpool L69 3GE, U.K., Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K., Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Drug Discovery, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, Medicines Research Centre, GlaxoSmithKline, Gunnels Wood
| | - Phil Roberts
- Department of Chemistry, University of Liverpool, Liverpool L69 7ZD, U.K., MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, School of Biomedical Sciences, University of Liverpool, Liverpool L69 3GE, U.K., Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K., Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Drug Discovery, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, Medicines Research Centre, GlaxoSmithKline, Gunnels Wood
| | - Paul A. Stocks
- Department of Chemistry, University of Liverpool, Liverpool L69 7ZD, U.K., MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, School of Biomedical Sciences, University of Liverpool, Liverpool L69 3GE, U.K., Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K., Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Drug Discovery, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, Medicines Research Centre, GlaxoSmithKline, Gunnels Wood
| | - Giancarlo Biagini
- Department of Chemistry, University of Liverpool, Liverpool L69 7ZD, U.K., MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, School of Biomedical Sciences, University of Liverpool, Liverpool L69 3GE, U.K., Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K., Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Drug Discovery, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, Medicines Research Centre, GlaxoSmithKline, Gunnels Wood
| | - Patrick G. Bray
- Department of Chemistry, University of Liverpool, Liverpool L69 7ZD, U.K., MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, School of Biomedical Sciences, University of Liverpool, Liverpool L69 3GE, U.K., Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K., Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Drug Discovery, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, Medicines Research Centre, GlaxoSmithKline, Gunnels Wood
| | - Jill Davies
- Department of Chemistry, University of Liverpool, Liverpool L69 7ZD, U.K., MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, School of Biomedical Sciences, University of Liverpool, Liverpool L69 3GE, U.K., Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K., Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Drug Discovery, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, Medicines Research Centre, GlaxoSmithKline, Gunnels Wood
| | - Neil Berry
- Department of Chemistry, University of Liverpool, Liverpool L69 7ZD, U.K., MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, School of Biomedical Sciences, University of Liverpool, Liverpool L69 3GE, U.K., Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K., Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Drug Discovery, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, Medicines Research Centre, GlaxoSmithKline, Gunnels Wood
| | - Charlotte Hall
- Department of Chemistry, University of Liverpool, Liverpool L69 7ZD, U.K., MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, School of Biomedical Sciences, University of Liverpool, Liverpool L69 3GE, U.K., Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K., Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Drug Discovery, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, Medicines Research Centre, GlaxoSmithKline, Gunnels Wood
| | - Karen Rimmer
- Department of Chemistry, University of Liverpool, Liverpool L69 7ZD, U.K., MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, School of Biomedical Sciences, University of Liverpool, Liverpool L69 3GE, U.K., Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K., Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Drug Discovery, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, Medicines Research Centre, GlaxoSmithKline, Gunnels Wood
| | - Peter A. Winstanley
- Department of Chemistry, University of Liverpool, Liverpool L69 7ZD, U.K., MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, School of Biomedical Sciences, University of Liverpool, Liverpool L69 3GE, U.K., Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K., Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Drug Discovery, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, Medicines Research Centre, GlaxoSmithKline, Gunnels Wood
| | - Stephen Hindley
- Department of Chemistry, University of Liverpool, Liverpool L69 7ZD, U.K., MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, School of Biomedical Sciences, University of Liverpool, Liverpool L69 3GE, U.K., Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K., Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Drug Discovery, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, Medicines Research Centre, GlaxoSmithKline, Gunnels Wood
| | - Ramesh B. Bambal
- Department of Chemistry, University of Liverpool, Liverpool L69 7ZD, U.K., MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, School of Biomedical Sciences, University of Liverpool, Liverpool L69 3GE, U.K., Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K., Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Drug Discovery, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, Medicines Research Centre, GlaxoSmithKline, Gunnels Wood
| | - Charles B. Davis
- Department of Chemistry, University of Liverpool, Liverpool L69 7ZD, U.K., MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, School of Biomedical Sciences, University of Liverpool, Liverpool L69 3GE, U.K., Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K., Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Drug Discovery, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, Medicines Research Centre, GlaxoSmithKline, Gunnels Wood
| | - Martin Bates
- Department of Chemistry, University of Liverpool, Liverpool L69 7ZD, U.K., MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, School of Biomedical Sciences, University of Liverpool, Liverpool L69 3GE, U.K., Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K., Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Drug Discovery, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, Medicines Research Centre, GlaxoSmithKline, Gunnels Wood
| | - Stephanie L. Gresham
- Department of Chemistry, University of Liverpool, Liverpool L69 7ZD, U.K., MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, School of Biomedical Sciences, University of Liverpool, Liverpool L69 3GE, U.K., Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K., Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Drug Discovery, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, Medicines Research Centre, GlaxoSmithKline, Gunnels Wood
| | - Richard A. Brigandi
- Department of Chemistry, University of Liverpool, Liverpool L69 7ZD, U.K., MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, School of Biomedical Sciences, University of Liverpool, Liverpool L69 3GE, U.K., Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K., Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Drug Discovery, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, Medicines Research Centre, GlaxoSmithKline, Gunnels Wood
| | - Federico M. Gomez-de-las-Heras
- Department of Chemistry, University of Liverpool, Liverpool L69 7ZD, U.K., MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, School of Biomedical Sciences, University of Liverpool, Liverpool L69 3GE, U.K., Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K., Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Drug Discovery, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, Medicines Research Centre, GlaxoSmithKline, Gunnels Wood
| | - Domingo V. Gargallo
- Department of Chemistry, University of Liverpool, Liverpool L69 7ZD, U.K., MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, School of Biomedical Sciences, University of Liverpool, Liverpool L69 3GE, U.K., Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K., Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Drug Discovery, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, Medicines Research Centre, GlaxoSmithKline, Gunnels Wood
| | - Silvia Parapini
- Department of Chemistry, University of Liverpool, Liverpool L69 7ZD, U.K., MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, School of Biomedical Sciences, University of Liverpool, Liverpool L69 3GE, U.K., Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K., Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Drug Discovery, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, Medicines Research Centre, GlaxoSmithKline, Gunnels Wood
| | - Livia Vivas
- Department of Chemistry, University of Liverpool, Liverpool L69 7ZD, U.K., MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, School of Biomedical Sciences, University of Liverpool, Liverpool L69 3GE, U.K., Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K., Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Drug Discovery, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, Medicines Research Centre, GlaxoSmithKline, Gunnels Wood
| | - Hollie Lander
- Department of Chemistry, University of Liverpool, Liverpool L69 7ZD, U.K., MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, School of Biomedical Sciences, University of Liverpool, Liverpool L69 3GE, U.K., Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K., Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Drug Discovery, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, Medicines Research Centre, GlaxoSmithKline, Gunnels Wood
| | - Donatella Taramelli
- Department of Chemistry, University of Liverpool, Liverpool L69 7ZD, U.K., MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, School of Biomedical Sciences, University of Liverpool, Liverpool L69 3GE, U.K., Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K., Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Drug Discovery, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, Medicines Research Centre, GlaxoSmithKline, Gunnels Wood
| | - Stephen A. Ward
- Department of Chemistry, University of Liverpool, Liverpool L69 7ZD, U.K., MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, School of Biomedical Sciences, University of Liverpool, Liverpool L69 3GE, U.K., Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K., Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Drug Discovery, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, Medicines Research Centre, GlaxoSmithKline, Gunnels Wood
| |
Collapse
|
39
|
Amodiaquine-induced oxidative stress in a hepatocyte inflammation model. Toxicology 2009; 256:101-9. [DOI: 10.1016/j.tox.2008.11.006] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2008] [Revised: 11/09/2008] [Accepted: 11/10/2008] [Indexed: 11/23/2022]
|
40
|
Johansson T, Jurva U, Grönberg G, Weidolf L, Masimirembwa C. Novel Metabolites of Amodiaquine Formed by CYP1A1 and CYP1B1: Structure Elucidation Using Electrochemistry, Mass Spectrometry, and NMR. Drug Metab Dispos 2008; 37:571-9. [DOI: 10.1124/dmd.108.025171] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
41
|
Synthesis and antimalarial activity of carbamate and amide derivatives of 4-anilinoquinoline. Eur J Med Chem 2008; 43:2045-55. [DOI: 10.1016/j.ejmech.2007.11.003] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2007] [Revised: 07/09/2007] [Accepted: 11/12/2007] [Indexed: 11/18/2022]
|
42
|
Abstract
Malaria, a disease transmitted by the female Anopheles mosquito, has had devastating effects on human populations for more than 4000 years. Treatment of the disease with single drugs, such as chloroquine, sulfadoxine/pyrimethamine or mefloquine, has led to the emergence of resistant Plasmodium falciparum parasites that lead to the most severe form of the illness. Artemisinin-based combination therapies are currently recommended by WHO for the treatment of uncomplicated P. falciparum malaria. Artemisinin and semisynthetic derivatives, including artesunate, artemether and dihydroartemisinin, are short-acting antimalarial agents that kill parasites more rapidly than conventional antimalarials, and are active against both the sexual and asexual stages of the parasite cycle. Artemisinin fever clearance time is shortened to 32 hours as compared with 2-3 days with older agents. To delay or prevent emergence of resistance, artemisinins are combined with one of several longer-acting drugs--amodiaquine, mefloquine, sulfadoxine/pyrimethamine or lumefantrine--which permit elimination of the residual malarial parasites. The clinical pharmacology of artemisinin-based combination therapies is highly complex. The short-acting artemisinins and their long-acting counterparts are metabolized and/or inhibit/induce cytochrome P450 enzymes, and may thus participate in drug-drug interactions with multiple drugs on the market. Alterations in antimalarial drug plasma concentrations may lead to either suboptimal efficacy or drug toxicity and may compromise treatment.
Collapse
Affiliation(s)
- Polina I German
- Drug Research Unit, University of California, San Francisco, California 94143-0622, USA.
| | | |
Collapse
|
43
|
Jurva U, Holmén A, Grönberg G, Masimirembwa C, Weidolf L. Electrochemical Generation of Electrophilic Drug Metabolites: Characterization of Amodiaquine Quinoneimine and Cysteinyl Conjugates by MS, IR, and NMR. Chem Res Toxicol 2008; 21:928-35. [DOI: 10.1021/tx700400c] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Ulrik Jurva
- AstraZeneca R&D Mölndal, S-431 83 Mölndal, Sweden
| | | | | | | | - Lars Weidolf
- AstraZeneca R&D Mölndal, S-431 83 Mölndal, Sweden
| |
Collapse
|
44
|
Delarue-Cochin S, Paunescu E, Maes L, Mouray E, Sergheraert C, Grellier P, Melnyk P. Synthesis and antimalarial activity of new analogues of amodiaquine. Eur J Med Chem 2008; 43:252-60. [PMID: 17485145 DOI: 10.1016/j.ejmech.2007.03.008] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2006] [Revised: 03/02/2007] [Accepted: 03/08/2007] [Indexed: 11/28/2022]
Abstract
In order to determine the real significance of the 4'-phenolic group in the antimalarial activity and/or cytotoxicity of amodiaquine (AQ), analogues for which this functionality was shifted or modified were synthesized. Good in vitro antimalarial activity was obtained for compounds unable to form intramolecular hydrogen bond. Among the compounds synthesized, new amino derivative 5 displayed the greatest selectivity index towards the most CQ-resistant strain tested and was active in mice infected by Plasmodium berghei.
Collapse
Affiliation(s)
- Sandrine Delarue-Cochin
- UMR CNRS 8525, Université de Lille II, Institut Pasteur de Lille 1 rue du Professeur Calmette, B.P. 447, 59021 Lille cedex, France
| | | | | | | | | | | | | |
Collapse
|
45
|
Park KB, Dalton-Brown E, Hirst C, Williams DP. Selection of new chemical entities with decreased potential for adverse drug reactions. Eur J Pharmacol 2006; 549:1-8. [PMID: 16979156 DOI: 10.1016/j.ejphar.2006.08.025] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2006] [Revised: 07/25/2006] [Accepted: 08/02/2006] [Indexed: 01/08/2023]
Abstract
Adverse drug reactions, such as hepatotoxicity, blood dyscrasias and hypersensitivity are a major obstacle for the use and the development of new medicines. Many forms of organ-directed toxicity can arise from the bioactivation of drugs to so-called chemically reactive metabolites, which can modify tissue macromolecules. It is well established that the toxicities of model hepatotoxins, such as acetaminophen, furosemide, bromobenzene and methapyrilene can be correlated with the generation of chemically reactive metabolites, which can be detected by measurement of the irreversible binding of radiolabelled material to hepatic protein and/or the detection of stable phase II metabolites such as glutathione conjugates. The basic chemistry of the reaction of such metabolites with model nucleophiles is relatively well understood. A major challenge is to define how certain reactive intermediates may chemically modify critical proteins and how modification of specific amino acids may alter protein function which in turn may affect cell signalling, regulation, defence, function and viability. This in turn will determine whether or not bioactivation will result in a particular form of drug-induced injury. It is now clear that even relatively simple reactive intermediates can react in a discriminative manner with particular cellular proteins and even with specific amino acids within those proteins. Therefore both non-covalent, as well as covalent bonds will be important determinants of the target protein for a particular reactive metabolite. Mammalian cells have evolved numerous defence systems against reactive intermediates. Sensitive redox proteins such as Nrf-2 recognize oxidative stress and electrophilic agents. This is achieved by chemical modification of cysteine groups within keap-1, which normally forms an inactive heterodimer with Nrf-2. Modification of keap-1 releases Nrf-2 that translocates to the nucleus and effects gene transcription of a number of genes involved in the detoxication of chemically reactive metabolites. Diminution of protein function can occur by either covalent modification of nucleophilic amino acids (e.g. cysteine, lysine, histidine etc.) or oxidation of thiols, which can be reversible or irreversible. In the case of acetaminophen, more than 30 target proteins have been identified and for several of them, corresponding alterations in protein function have been defined in the context of tissue necrosis. Alternatively, protein modification may induce signalling systems which initiate cell death, an immune response or to an altered tissue genotype.
Collapse
Affiliation(s)
- Kevin B Park
- Drug Safety Research Group, Department Pharmacology and Therapeutics, University of Liverpool, Sherrington Building, Ashton St., L69 3GE, United Kingdom
| | | | | | | |
Collapse
|
46
|
Williams DP. Toxicophores: Investigations in drug safety. Toxicology 2006; 226:1-11. [DOI: 10.1016/j.tox.2006.05.101] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2006] [Accepted: 05/26/2006] [Indexed: 02/03/2023]
|
47
|
Ip J, Uetrecht JP. In vitro and animal models of drug-induced blood dyscrasias. ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY 2006; 21:135-140. [PMID: 21783650 DOI: 10.1016/j.etap.2005.07.003] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Drug-induced blood dyscrasias can be either acute and predictable or delayed and unpredictable (idiosyncratic). The predictable toxicity is relatively easy to reproduce with in vitro models, although they may not work for drugs that require bioactivation. It is very unlikely that idiosyncratic blood dyscrasias can be modeled in vitro, although some drugs (or their reactive metabolites) that cause idiosyncratic reaction are toxic to bone marrow cells in vitro. Although the mechanisms of idiosyncratic reactions are poorly understood, there is evidence that most are due to reactive metabolites and some are immune-mediated. Therefore screening drugs for their bioactivation by myeloperoxidase, the major oxidative enzyme in bone marrow, may provide some measure of the risk that a drug will cause blood dyscrasias. Several examples of drug-induced idiosyncratic agranulocytosis, aplastic anemia and thrombocytopenia are presented, but better in vivo models are clearly needed to gain a clearer understanding of these adverse reactions.
Collapse
Affiliation(s)
- Julia Ip
- Faculty of Pharmacy, University of Toronto, 19 Russell Street, Toronto, Canada M5S 2S2
| | | |
Collapse
|
48
|
Uetrecht J. Role of animal models in the study of drug-induced hypersensitivity reactions. AAPS JOURNAL 2006; 7:E914-21. [PMID: 16594644 PMCID: PMC2750961 DOI: 10.1208/aapsj070489] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Drug-induced hypersensitivity reactions (DHRs) are a major problem, in large part because of their unpredictable nature. If we understood the mechanisms of these reactions better, they might be predictable. Their unpredictable nature also makes mechanistic studies very difficult, especially prospective clinical studies. Animal models are vital to most biomedical research, and they are almost the only way to test basic hypotheses of DHRs, such as the involvement of reactive metabolites. However, useful animal models of DHRs are rare because DHRs are also unpredictable in animals. For example, sulfonamide-induced DHRs in large-breed dogs appear to be valid because they are very similar to the DHRs that occur in humans; however, the incidence is only approximately 0.25%, and large-breed dogs are difficult to use as an animal model. Two more practical models are penicillamine-induced autoimmunity in the Brown Norway rat and nevirapine-induced skin rash in rats. The toxicity in these models is clearly immune mediated. In other models, such as amodiaquine-induced agranulocytosis/hepatotoxicity and halothane-induced hepatotoxicity, the drug induces an immune response but there is no clinical toxicity. This finding suggests that regulatory mechanisms usually limit toxicity. Many of the basic characteristics of the penicillamine and nevirapine models, such as memory and tolerance, are quite different suggesting that the mechanisms are also significantly different. More animal models are needed to study the range of mechanisms involved in DHRs; without them, progress in understanding such reactions is likely to be slow.
Collapse
Affiliation(s)
- Jack Uetrecht
- Department of Pharmacology, Clinical Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
| |
Collapse
|
49
|
Kalgutkar AS, Soglia JR. Minimising the potential for metabolic activation in drug discovery. Expert Opin Drug Metab Toxicol 2005; 1:91-142. [PMID: 16922655 DOI: 10.1517/17425255.1.1.91] [Citation(s) in RCA: 173] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Investigations into the role of bioactivation in the pathogenesis of xenobiotic-induced toxicity have been a major area of research since the link between reactive metabolites and carcinogenesis was first reported in the 1930s. Circumstantial evidence suggests that bioactivation of relatively inert functional groups to reactive metabolites may contribute towards certain drug-induced adverse reactions. Reactive metabolites, if not detoxified, can covalently modify essential cellular targets. The identity of the susceptible biomacromolecule(s), and the physiological consequence of its covalent modification, will dictate the resulting toxicological response (e.g., covalent modification of DNA by reactive intermediates derived from procarcinogens that potentially leads to carcinogenesis). The formation of drug-protein adducts often carries a potential risk of clinical toxicities that may not be predicted from preclinical safety studies. Animal models used to reliably predict idiosyncratic drug toxicity are unavailable at present. Furthermore, considering that the frequency of occurrence of idiosyncratic adverse drug reactions (IADRs) is fairly rare (1 in 1000 to 1 in 10,000), it is impossible to detect such phenomena in early clinical trials. Thus, the occurrence of IADRs during late clinical trials or after a drug has been released can lead to an unanticipated restriction in its use and even in its withdrawal. Major themes explored in this review include a comprehensive cataloguing of bioactivation pathways of functional groups commonly utilised in drug design efforts with appropriate strategies towards detection of corresponding reactive intermediates. Several instances wherein replacement of putative structural alerts in drugs associated with IADRs with a latent functionality eliminates the underlying liability are also presented. Examples of where bioactivation phenomenon in drug candidates can be successfully abrogated via iterative chemical interventions are also discussed. Finally, appropriate strategies that aid in potentially mitigating the risk of IADRs are explored, especially in circumstances in which the structural alert is also responsible for the primary pharmacology of the drug candidate and cannot be replaced.
Collapse
Affiliation(s)
- Amit S Kalgutkar
- Pfizer Global Research & Development, Pharmacokinetics, Dynamics and Metabolism Department, Groton, CT 06340, USA.
| | | |
Collapse
|
50
|
Abstract
Idiosyncratic drug reactions represent a major problem. In most cases the mechanisms of these reactions are unknown, but circumstantial evidence points to the involvement of reactive metabolites and the characteristics of the reactions suggest involvement of the immune system. If progress is to be made in dealing with these adverse reactions it is essential that we have a better understanding of their mechanisms, and it is hard to imagine testing mechanistic hypotheses without good animal models. Unfortunately, idiosyncratic reactions are also idiosyncratic in animals so few good models exist. The best models, in which a rodent develops a clinical syndrome similar to that which occurs in humans, appear to be penicillamine-induced autoimmunity in Brown Norway rats and nevirapine-induced skin rash in rats. Sulfamethoxazole-induced hypersensitivity in dogs and propylthiouracil-induced autoimmunity in cats are also similar to adverse reactions that occur in people, but they have practical limitations. Halothane-induced liver toxicity in guinea pigs and amodiaquine-induced bone marrow and liver toxicity in rats represent models in which there is an immune response and mild, reversible toxicity. It is possible that the development of immune tolerance is what limits the toxicity in these models, and if this is true, interventions that prevent tolerance might lead to good models. Although the history of developing animal models of idiosyncratic drug reactions is mostly one of failure, such models are essential. A better understanding of immune tolerance may greatly facilitate the development of better models; transgenic technology may also provide an important tool.
Collapse
Affiliation(s)
- Jacintha M Shenton
- Faculty of Pharmacy, University of Toronto, 19 Russell Street, Toronto, Ont., Canada M5S 2S2
| | | | | |
Collapse
|